Rosacea INO Gel (Ivermectin / Niacinamide / Oxymetazoline HCl) (30 mL)

Rosacea INO Gel is a targeted skincare treatment designed to soothe and manage symptoms of rosacea, a common skin condition that causes redness, inflammation, and visible blood vessels. The gel helps calm irritated skin while improving its texture and overall appearance. Its lightweight formula absorbs quickly, making it suitable for sensitive skin that is prone to flare-ups. With consistent use, Rosacea INO Gel supports skin health by reducing redness and discomfort while promoting a balanced and smoother complexion.

Rosacea INO Gel works by addressing the underlying causes of inflammation and skin sensitivity. It contains active ingredients that help reduce redness and prevent flare-ups by calming irritated blood vessels. The gel’s anti-inflammatory properties support the skin’s natural barrier function, helping to retain moisture and prevent dryness. Additionally, it assists in soothing nerve endings, which can decrease the burning or stinging sensations often associated with rosacea. Over time, the product helps strengthen the skin’s defenses, making it more resilient to environmental triggers.

Rosacea INO Gel should be used cautiously by individuals with known allergies to any of its components. Avoid applying the gel to broken or infected skin, as this can increase irritation or worsen symptoms. It is recommended to perform a patch test before full application to ensure compatibility with your skin. If you experience severe irritation, excessive dryness, or discomfort, discontinue use and consult a healthcare provider. Keep the product away from eyes, lips, and mucous membranes. Children should not use this product unless directed by a physician.

Some users of Rosacea INO Gel may experience mild reactions during the initial period of use. Common side effects include temporary redness, stinging, dryness, or slight peeling at the application site. These reactions usually subside as the skin adjusts to the treatment. However, in rare cases, individuals with highly sensitive skin may experience more intense irritation, swelling, or discomfort. Most side effects are minor and resolve without long-term issues when the product is used as directed.

Pregnant and breastfeeding women should consult their healthcare provider before using Rosacea INO Gel. Although the product is generally well tolerated and applied topically, some ingredients may be absorbed through the skin, and changes in hormonal levels during pregnancy can increase skin sensitivity. A medical professional can help determine whether it is safe to use the gel during pregnancy or while nursing. When used under proper guidance, it can be part of a skin care routine that minimizes discomfort while supporting healthy skin.

Store this medication in its original container at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light. Keep all medicine out of the reach of children. Throw away any unused medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain.

1. Chouela E, Abeldano A, et el. Arch Dematol 1999;135:651-5.
2. del Giudice P, Chosidow O, Caumes E. Ivermectin in dermatology. J Drugs Dermatol 2003;2:13-21.
3. Richard-Lenoble D, Chandenier J, and Gaxotte P. Ivermectin and filariasis. Fundam Clin Pharmacology 2003;17:199-203.
4. Ottesen EA, Campbell WC. Ivermectin in human medicine. J Antimicrobial Chemotherapy 1994;34:195-203.
5. Niaspan (niacin extended-release) tablet package insert. North Chicago, IL: Abbott Laboratories; 2015 Apr.
6. HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203-12.
7. Taylor AJ, Villines TC, Stanck EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009. Epub ahead of print, doi:10.1056/NEJMoa907569.
8. Lee JMS, Robson MD, Yu LM, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: A randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009;54:1787—94.
9. McKenney JM, et al. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672-7.
10. Rhofade (oxymetazoline hydrochloride cream) package insert. Irvine, CA: Allergan; 2017 Jan.
11. Afrin No Drip Extra Moisturizing (oxymetazoline hydrochloride spray, metered) package insert. Whippany, NJ: Bayer Healthcare LLC; 2016 Aug.
12. Visine LR (oxymetazoline hydrochloride 0.025% solution) package insert. Fort Washington, PA: Johnson and Johnson Healthcare Products, Inc.; 2010 Apr.
13. Stromectol (ivermectin) package insert. Whitehouse Station, NJ: Merck and Co., Inc.; 2018 Feb.
14. Sklice (ivermectin lotion) package insert. Atlanta, GA: Arbor Pharmaceuticals; 2017 Jun.
15. Soolantra (ivermectin) package insert. Fort Worth, TX: Galderma Laboratories; 2018 Apr.
16. National Institutes of Health (NIH). Ivermectin monograph. LactMed: Drug and Lactation Database. Available at http://toxnet.nlm.nih.gov/cgi-bin/sis/search/f?./temp/~tx6AqM:1.– LinkOpens in New Tab Accessed February 9, 2012.
17. American Academy of Pediatrics (AAP) Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108(3):776-789.
18. Colletti RB, Neufeld EJ, Roff NK, et al. Niacin treatment of hypercholesterolemia in children. Pediatrics 1993;92:78-82.
19. Expert Panel: National Cholesterol Education Program. Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 1992;89(suppl 2):525-84.
20. Niacinamide. In: Drugs in Pregnancy and Lactation. A Reference Guide to Fetal and Neonatal Risk. Briggs GG, Freeman RK, Yaffe SJ, (eds.) 7th ed., Philadelphia PA: Lippincott Williams and Wilkins; 2005:1140-1
21. Health Care Financing Administration. Interpretive Guidelines for Long-term Care Facilities. Title 42 CFR 483.25(l) F329: Unnecessary Drugs. Revised 2015.
22. Homeida MM, Bagi IA, Ghalib HW, et al. Prolongation of prothrombin time with ivermectin. Lancet 1988;1:1346-7..
23. Whitworth JA, Hay CR, McNicholas AM, et al. Coagulation abnormalities and ivermectin. Ann Trop Med Parasitol 1992;86:301-5.
24. Richards FO, McNeely MB, Bryan RT, et al. Ivermectin and prothrombin time. Lancet 1989;1:1139.
25. Pacque MC, Munoz B, White AT, et al. Ivermectin and prothrombin time. Lancet 1989;1:1140.
26. Niacor (Niacin tablets) package insert. Minneapolis, MN: Upsher-Smith Laboratories, Inc.; 2000 Feb.
27. FDA Drug Safety Communication. Over-The-Counter Eye Drops and Nasal Sprays- Serious Adverse Events from Accidental Ingestion by Children. Retrieved Oct. 25, 2012. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm325729.htm?source=govdeliver